XML 56 R27.htm IDEA: XBRL DOCUMENT v3.22.0.1
Revenue (Tables)
 9 Months Ended
Jan. 28, 2022
Revenue from Contract with Customer [Abstract]  
Disaggregation of Revenue
The table below illustrates net sales by segment and division for the three and nine months ended January 28, 2022 and January 29, 2021:
 
Three months ended
Nine months ended
(in millions)January 28, 2022January 29, 2021January 28, 2022January 29, 2021
Cardiac Rhythm & Heart Failure $1,402 $1,371 $4,356 $4,045 
Structural Heart & Aortic740 730 2,277 2,090 
Coronary & Peripheral Vascular 603 605 1,829 1,730 
Cardiovascular 2,745 2,707 8,462 7,865 
Surgical Innovations1,519 1,423 4,570 3,896 
Respiratory, Gastrointestinal, & Renal771 890 2,341 2,502 
Medical Surgical 2,290 2,313 6,910 6,399 
Cranial & Spinal Technologies1,102 1,081 3,292 3,096 
Specialty Therapies633 618 1,908 1,653 
Neuromodulation409 426 1,285 1,152 
Neuroscience 2,144 2,126 6,484 5,900 
Diabetes 584 630 1,741 1,766 
Total$7,763 $7,775 $23,597 $21,929 

The table below illustrates net sales by market geography for each segment for the three and nine months ended January 28, 2022 and January 29, 2021:
 
U.S.(1)
Non-U.S. Developed Markets(2)
Emerging Markets(3)
Three months endedThree months endedThree months ended
(in millions)January 28, 2022January 29, 2021January 28, 2022January 29, 2021January 28, 2022January 29, 2021
Cardiovascular $1,297 $1,272 $935 $941 $513 $493 
Medical Surgical 990 959 812 868 488 486 
Neuroscience 1,397 1,401 431 444 316 280 
Diabetes 255 307 261 268 68 55 
Total$3,939 $3,939 $2,438 $2,522 $1,385 $1,314 
U.S.(1)
Non-U.S. Developed Markets(2)
Emerging Markets(3)
Nine months endedNine months endedNine months ended
(in millions)January 28, 2022January 29, 2021January 28, 2022January 29, 2021January 28, 2022January 29, 2021
Cardiovascular $4,090 $3,854 $2,886 $2,739 $1,486 $1,271 
Medical Surgical 2,950 2,677 2,521 2,425 1,439 1,297 
Neuroscience 4,237 3,934 1,330 1,246 918 720 
Diabetes 760 879 780 733 201 154 
Total$12,038 $11,344 $7,517 $7,143 $4,043 $3,443 
(1)U.S. includes the United States and U.S. territories.
(2)Non-U.S. developed markets include Japan, Australia, New Zealand, Korea, Canada, and the countries within Western Europe.
(3)Emerging markets include the countries of the Middle East, Africa, Latin America, Eastern Europe, and the countries of Asia that are not included in the non-U.S. developed markets, as defined above.